deltatrials
Completed PHASE2 NCT00080353

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

Phase II Study in Metastatic Melanoma Using Lymphocytes Reactive With the gp100 Antigen and Immunization Using a Recombinant rF-gp100P209 Virus Encoding a gp100 Peptide Following a Nonmyeloablative Lymphocyte Depleting Regimen

Sponsor: National Cancer Institute (NCI)

Conditions Melanoma
Interventions IL-2 Montanide ISA 51 OKT3 gp100:209-217 rF-go 100P209
Updated 5 times since 2017 Last updated: Jun 12, 2012 Started: Mar 31, 2004 Primary completion: Dec 31, 2007 Completion: Dec 31, 2008

A PHASE2 clinical study on Melanoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 5 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States